E Gluckman

Summary

Country: France

Publications

  1. ncbi Cord blood transplantation
    Eliane Gluckman
    Hospital Saint Louis, Paris, France
    Biol Blood Marrow Transplant 12:808-12. 2006
  2. ncbi Donor selection for unrelated cord blood transplants
    Eliane Gluckman
    Department of Hematology Bone Marrow Transplant, EUROCORD, Institute of Hematology, APHP Hospital Saint Louis, Paris, France
    Curr Opin Immunol 18:565-70. 2006
  3. ncbi Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival
    Eliane Gluckman
    Hôpital Saint Louis AP HP, University of Paris VII, IUH, Paris, France
    Biol Blood Marrow Transplant 13:1073-82. 2007
  4. ncbi History of cord blood transplantation
    E Gluckman
    EUROCORD, Hospital Saint Louis, and University Paris VII, Paris, France
    Bone Marrow Transplant 44:621-6. 2009
  5. ncbi Ten years of cord blood transplantation: from bench to bedside
    Eliane Gluckman
    Hospital Saint Louis APHP, University Paris VII, Institut Universitaire d Hematologie, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Br J Haematol 147:192-9. 2009
  6. ncbi Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome
    E Gluckman
    Hematology Department, Eurocord Hôpital, Saint Louis, Paris, France
    Bone Marrow Transplant 41:127-32. 2008
  7. ncbi Milestones in umbilical cord blood transplantation
    Eliane Gluckman
    EUROCORD, Assistance publique des Hôpitaux de Paris APHP, Institut Universitaire d Hématologie IUH Hôpital Saint Louis, Paris, France
    Br J Haematol 154:441-7. 2011
  8. ncbi Family-directed umbilical cord blood banking
    Eliane Gluckman
    EUROCORD, Hospital Saint Louis, University Paris VII, Paris, France
    Haematologica 96:1700-7. 2011
  9. ncbi Milestones in umbilical cord blood transplantation
    E Gluckman
    EUROCORD, Assistance publique des Hôpitaux de Paris APHP, Institut universitaire d Hématologie IUH Hospital Saint Louis Paris, France
    Blood Rev 25:255-9. 2011
  10. ncbi Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia
    Renata Bizzetto
    Eurocord Hospital Saint Louis, Paris Cedex 10, France
    Haematologica 96:134-41. 2011

Collaborators

Detail Information

Publications143 found, 100 shown here

  1. ncbi Cord blood transplantation
    Eliane Gluckman
    Hospital Saint Louis, Paris, France
    Biol Blood Marrow Transplant 12:808-12. 2006
  2. ncbi Donor selection for unrelated cord blood transplants
    Eliane Gluckman
    Department of Hematology Bone Marrow Transplant, EUROCORD, Institute of Hematology, APHP Hospital Saint Louis, Paris, France
    Curr Opin Immunol 18:565-70. 2006
    ..Methods of improving engraftment are currently under investigation...
  3. ncbi Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival
    Eliane Gluckman
    Hôpital Saint Louis AP HP, University of Paris VII, IUH, Paris, France
    Biol Blood Marrow Transplant 13:1073-82. 2007
    ..In conclusion, factors easily modifiable such as donor selection and a Fludarabine-containing regimen can considerably improve survival in FA patients given a UCBT. These data are the basis for designing prospective protocols...
  4. ncbi History of cord blood transplantation
    E Gluckman
    EUROCORD, Hospital Saint Louis, and University Paris VII, Paris, France
    Bone Marrow Transplant 44:621-6. 2009
    ..In the absence of ethical concern, the unlimited supply of cells explains the increasing interest of using cord blood for developing regenerative medicine...
  5. ncbi Ten years of cord blood transplantation: from bench to bedside
    Eliane Gluckman
    Hospital Saint Louis APHP, University Paris VII, Institut Universitaire d Hematologie, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Br J Haematol 147:192-9. 2009
    ..In addition to haematopoietic stem cells, cord blood and placenta contain a high number of non-haematopoietic stem cells that explains the increasing interest of using cord blood for developing regenerative medicine...
  6. ncbi Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome
    E Gluckman
    Hematology Department, Eurocord Hôpital, Saint Louis, Paris, France
    Bone Marrow Transplant 41:127-32. 2008
    ..In this review, we will report recent results of treatment of Fanconi anemia and other hereditary BMF syndromes...
  7. ncbi Milestones in umbilical cord blood transplantation
    Eliane Gluckman
    EUROCORD, Assistance publique des Hôpitaux de Paris APHP, Institut Universitaire d Hématologie IUH Hôpital Saint Louis, Paris, France
    Br J Haematol 154:441-7. 2011
    ..The absence of ethical concern and the unlimited supply of cells explain the increasing interest of using UCB for developing regenerative medicine...
  8. ncbi Family-directed umbilical cord blood banking
    Eliane Gluckman
    EUROCORD, Hospital Saint Louis, University Paris VII, Paris, France
    Haematologica 96:1700-7. 2011
    ....
  9. ncbi Milestones in umbilical cord blood transplantation
    E Gluckman
    EUROCORD, Assistance publique des Hôpitaux de Paris APHP, Institut universitaire d Hématologie IUH Hospital Saint Louis Paris, France
    Blood Rev 25:255-9. 2011
    ..The absence of ethical concern, and the unlimited supply of cells explain the increasing interest of using cord blood for developing regenerative medicine...
  10. ncbi Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia
    Renata Bizzetto
    Eurocord Hospital Saint Louis, Paris Cedex 10, France
    Haematologica 96:134-41. 2011
    ..Allogeneic stem cell transplantation is the only curative option for patients with hereditary bone marrow failure syndromes. Umbilical cord blood is an alternative source of stem cells for allogeneic transplantation...
  11. ncbi Results of unrelated umbilical cord blood hematopoietic stem cell transplant
    E Gluckman
    Eurocord Hematology Bone Marrow Transplant Department, Hospital Saint Louis, Paris, France
    Transfus Clin Biol 8:146-54. 2001
    ..In conclusion, this large registry study confirms the potential benefit of using umbilical cord blood hematopoietic stem cells for allogeneic transplants...
  12. ncbi A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors
    M Robin
    , , APHP, Paris, Cedex, France
    Leukemia 19:1613-20. 2005
    ..We conclude that allogeneic transplantation with a related donor can cure more than half of CML patients in chronic phase, although physicians should be alert to long-term complications...
  13. ncbi Cord blood banking and transplant in Europe. Eurocord
    E Gluckman
    Hopital Saint Louis, Paris, France
    Vox Sang 74:95-101. 1998
    ....
  14. ncbi Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia
    V Rocha
    Department of Hematology and Bone Marrow Transplant Unit, University of Paris 7, Hopital Saint Louis, Paris, France
    Leukemia 23:545-56. 2009
    ..04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively...
  15. ncbi Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies
    C Ferry
    Hematopoietic Stem Cell Transplant, Hopital Saint Louis, Paris, France
    Bone Marrow Transplant 40:219-24. 2007
    ..With increased follow-up, development of late effects and of psycho-social disturbance are of major concern. While the use of single-dose TBI has now been abandoned, other risk factors are still of concern in the early 2000s...
  16. ncbi Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation
    L Garderet
    Service d hématologie greffe de moelle, Hopital Saint Louis, Paris, France
    Eur J Haematol 66:137-9. 2001
    ..T-prolymphocytic leukemia (T-PLL) is a rare disease of the elderly characterized by a high white blood cell count and organomegaly, and is currently incurable. Our aim was to elicit graft-versus-leukemia reactions in a patient with T-PLL...
  17. ncbi Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia
    R Morariu-Zamfir
    Laboratory of Cellular Therapy, Saint Louis Hospital, Paris, France
    Bone Marrow Transplant 27:575-80. 2001
    ..5 (95% CI: 1.09-5.75), P = 0.03) and a lower number of marrow CD34(+) cells infused/kg (HR: 4.55 (95% CI: 1.87-10.90), P = 0.0008)...
  18. ncbi Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders
    H Bittencourt
    Bone Marrow Transplant Unit, Hospital Saint-Louis, Paris, France
    Bone Marrow Transplant 36:431-5. 2005
    ..02) and GVHD (P = 0.005) were associated with higher risk of death. In conclusion, hematological response after 3 days with G-CSF predicted a better survival for patients with PGF after allo-SCT...
  19. ncbi Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation
    G Socie
    Hematologie Greffe de Moelle, Hospital Saint Louis, Paris, France
    Br J Haematol 113:194-201. 2001
    ..4, P = 0.04). Decreased bone density was associated with chronic GvHD (OR = 3.9, P = 0.001). Thus, using routine tests in adult patients we were able to detect significant numbers of-non-symptomatic complications enabling early treatment...
  20. ncbi Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality
    M Robin
    Haematology Department, Bone Marrow Transplant Unit, Hospital Saint Louis, Paris, France
    Bone Marrow Transplant 31:877-87. 2003
    ..The analysis strongly suggests that the combination of pretransplant factors such as chemotherapy and conditioning, and posttransplant factors such as chronic GvHD had a major impact on late nonrelapse morbidity and mortality...
  21. ncbi Allogeneic hematopoietic stem cell transplantation: current issues and future prospects
    G Socie
    Service de Greffe de Moelle, Hopital Saint Louis, Paris, France
    Ann Med Interne (Paris) 150:642-55. 1999
    ..These issues and prospects will include; stem cell sources, alternative donors, graft-versus-host disease, indications and long-term survival following allogeneic stem cell transplantation...
  22. ncbi KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia
    R Willemze
    Clinical Research Unit, Eurocord Office, APHP, Hopital Saint Louis, Université de Paris VII, Paris, France
    Leukemia 23:492-500. 2009
    ..012), and 5 versus 36% (P=0.005), respectively). UCBT for acute leukemia in CR from KIR-ligand-incompatible donors is associated with decreased RI and improved LFS and OS...
  23. ncbi Double cord blood transplantation in patients with high risk bone marrow failure syndromes
    A Ruggeri
    Service d Hématologie Greffe, Hopital Saint Louis, APHP, Paris University 7, Paris, France
    Br J Haematol 143:404-8. 2008
    ..Transplantation of two partially HLA-matched UCB thus enables salvage treatment of high-risk patients with BMFS...
  24. ncbi Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry
    J Donadieu
    Service d hématologie et oncologie pédiatrique, Hopital Trousseau, Paris, France
    Bone Marrow Transplant 36:787-92. 2005
    ..The overall 5-year event-free survival rate is 60+/-15%. We conclude that HSCT is feasible for patients with SDS who develop bone marrow failure or malignant transformation...
  25. ncbi Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis
    A Ruggeri
    EUROCORD, Hôpital Saint Louis APHP, University Paris VII IUH Paris, France
    Leukemia 26:2455-61. 2012
    ..Approaches that may decrease relapse incidence in children given UCBT with positive MRD should be investigated to improve final outcomes...
  26. ncbi Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases
    A Ruggeri
    Service d Hématologie Greffe, Hopital Saint Louis, APHP, Paris University 7, Paris, France
    Transpl Infect Dis 13:456-65. 2011
    ..Delayed immune recovery and high incidence of infectious complications were observed after dUCBT in patients with high-risk hematological diseases...
  27. ncbi Effect of tresperimus on in vitro human cord blood CD34+ cell differentiation
    S el Marsafy
    Laboratoire de Recherche sur la Biologie de la Moelle Osseuse, Institut Universitaire d Hematologie, Hĵpital Saint Louis, Paris, France
    Haematologia (Budap) 31:139-46. 2001
    ..These results may be of clinical interest as tresperimus is currently used in phase I-III studies for the prevention of graft versus host disease in recipients of allogeneic bone marrow...
  28. ncbi Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients
    S Maury
    Department of Haematology-Bone Marrow Transplant, , Paris, France
    Br J Haematol 115:630-41. 2001
    ....
  29. ncbi Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process
    G Socie
    Service d hématologie greffe de moelle, Unité de Recherche sur la Biologie des Cellules Souches, Hopital Saint Louis, Paris, France
    Transplantation 66:667-70. 1998
    ..The tumor suppressor gene p53 has been strongly linked to the occurrence of SCC in the nonimmunocompromised population...
  30. ncbi Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia
    Vanderson Rocha
    , , Paris, France
    N Engl J Med 351:2276-85. 2004
    ..CONCLUSIONS: Cord blood from an unrelated donor is an alternative source of hematopoietic stem cells for adults with acute leukemia who lack an HLA-matched bone marrow donor...
  31. ncbi Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation
    P Ribaud
    Departement de Biostatistique et Informatique Medicale, Hopital Saint Louis, Paris, France
    Clin Infect Dis 28:322-30. 1999
    ..0001)...
  32. ncbi Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT
    M Robin
    Service d Hématologie Greffe, Hopital Saint Louis, APHP, Paris, France
    Leukemia 25:75-81. 2011
    ..76; P=0.047). In spite of high NRM, these data indicate that UCBT is an acceptable alternative option to treat adults with high-risk MDS or sAML, without a suitable human leukocyte antigen (HLA)-matched donor...
  33. ncbi History of the clinical use of umbilical cord blood hematopoietic cells
    E Gluckman
    Department of Hematology, Bone Marrow Transplant and Eurocord Netcord Registry, Hospital Saint Louis, Paris, France
    Cytotherapy 7:219-27. 2005
    ..able to overcome the HLA barrier and authorize HLA-mismatched transplants? Is it possible to establish CB banks for unrelated and related transplants? What would be the criteria for collection, quality control and cryopreservation?..
  34. ncbi Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation
    A Bergeron
    Service de Pneumologie, Hopital Saint Louis, Universite Paris 7, UFR Denis Diderot, Assistance Publique Hopitaux de Paris, Paris, France
    Bone Marrow Transplant 39:547-53. 2007
    ..02). These encouraging results provide new insights in the therapeutic approach of BO after SCT and require confirmation in a larger group of patients with a longer follow-up...
  35. ncbi Toxoplasmic pneumonitis leading to fatal acute respiratory distress syndrome after engraftment in three bone marrow transplant recipients
    N Ortonne
    Department of Pathology, , Paris, France
    Transplantation 72:1838-40. 2001
    ..Early screening of parasitemia using highly sensitive polymerase chain reaction methods in seropositive patients with unexplained fever may be needed...
  36. ncbi Hematopoietic stem-cell transplantation using umbilical-cord blood cells
    Vanderson Rocha
    Eurocord Office-Bone and Marrow Transplant Hematology Department, Hospital Saint Louis, Paris, France
    Rev Invest Clin 57:314-23. 2005
  37. ncbi Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice
    Eliane Gluckman
    Bone Marrow Transplant Unit and Eurocord Registry, Laboratory of Clinical Research on Cell Therapy, Saint Louis Hospital AP HP University Paris VII, Paris, France
    Exp Hematol 32:397-407. 2004
    ..Optimizing cord blood donor selection based mainly on cell dose and human leukocyte antigen (HLA) disparities may further improve results of unrelated cord blood transplants (UCBT)...
  38. ncbi Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study
    N De Castro
    Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Bone Marrow Transplant 36:879-83. 2005
    ..Long-term PCP prophylaxis should be maintained in patients receiving immunosuppressive drugs, and in those with low CD4+ T cell counts or a relapse of their hematological malignancy...
  39. ncbi Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis
    J Larghero
    Cell Therapy Unit, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, Paris, France
    Ann Rheum Dis 67:443-9. 2008
    ..Mesenchymal stem cells (MSCs) have a potential immunomodulatory role in autoimmune disease; however, the qualitative properties and haematopoietic support capacity of MSCs derived from patients with autoimmune disease is unclear...
  40. ncbi Allogeneic stem cell transplantation for Fanconi Anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation
    P Guardiola
    Service de Greffe de Moelle, Hopital Saint Louis, Paris, France
    Bone Marrow Transplant 21:S24-7. 1998
    ..New approaches including autologous stem cell transplantations and gene therapy are currently explored...
  41. ncbi Indications and results of cord blood transplant in children with leukemia
    E Gluckman
    Eurocord Hematology Department, APHP University Paris VII, Paris, France
    Bone Marrow Transplant 41:S80-2. 2008
    ..In conclusion, UCB is a valuable alternative source of hematopoietic stem cell transplantation in children with acute leukemia who need an allogeneic transplant, but lack a suitable sibling donor...
  42. ncbi Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register
    C Ferry
    , , Paris, France
    Bone Marrow Transplant 35:45-50. 2005
    ....
  43. ncbi Pediatric related and unrelated cord blood transplantation for malignant diseases
    V Rocha
    Hopital Saint Louis, Paris, France
    Bone Marrow Transplant 44:653-9. 2009
    ..This review will analyze the current results of CBT for pediatric patients with malignant diseases and the advantages and limitations of using this stem cell source...
  44. ncbi Bone marrow transplantation for Fanconi anemia using low-dose cyclophosphamide/thoracoabdominal irradiation as conditioning regimen: chimerism study by the polymerase chain reaction
    G Socie
    Service de Greffe de Moelle, Hopital Saint Louis, Paris, France
    Blood 82:2249-56. 1993
    ..In conclusion, lowering the Cy dose in the conditioning regimen of patients with FA could still allow complete engraftment to occur, at least in patients with an identical sibling donor...
  45. ncbi Results of unrelated umbilical cord blood hematopoietic stem cell transplantation
    E Gluckman
    Eurocord Hematology Bone Marrow Transplant and Biostatistics Departments, Hospital Saint Louis, Paris, France
    Rev Clin Exp Hematol 5:87-99. 2001
    ..This large registry study confirms the potential benefit of using umbilical cord blood hematopoietic stem cells for allogeneic transplants...
  46. ncbi Evidence for the presence of the alternatively spliced HLA-G mRNA forms in human mononuclear cells from peripheral blood and umbilical cord blood
    M Kirszenbaum
    CEA DSV DPTE, Laboratoire d Immunoradiobiologie, , Paris, France
    Hum Immunol 43:237-41. 1995
    ..In contrast, we did not revealed any HLA-G transcript in CD34+ fraction of cord blood cells...
  47. ncbi Umbilical cord blood transplants
    E Gluckman
    Department of Hematology and Bone Marrow Transplant, Hospital Saint Louis, Paris, France
    Curr Opin Hematol 7:353-7. 2000
    ..These data confirm the potential benefit of using umbilical cord blood hematopoietic stem cells for allogeneic transplants...
  48. ncbi Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation
    A B M Madureira
    Eurocord Office, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, Paris, France
    Leukemia 25:449-54. 2011
    ..017. These data suggest that transplantation of mismatched UCB graft is an acceptable alternative for children without a matched sibling or suitably matched unrelated adult donor...
  49. ncbi Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation
    Emmanuel Clave
    Laboratoire d Immunologie et d Histocompatibilité Assistance Publique Hôpitaux de Paris AP HP, Institut National de la Santé et de la Recherche Médicale INSERM U396, Hopital Saint Louis, Paris, Cedex 10, France
    Blood 105:2608-13. 2005
    ..7, P = .02) were associated with a better survival. Therefore, recipient host thymic function assessment could be helpful in predicting HSCT outcome and identifying patients who require a close immunologic monitoring...
  50. ncbi Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome
    Philippe Guardiola
    , , Paris, France
    Blood 103:73-7. 2004
    ..The impact of AGvHD on survival may not be limited to the early posttransplantation period and may be a major risk factor for head and neck carcinomas and late mortality in FA patients...
  51. ncbi DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation
    P Loiseau
    Service d'Immunologie et d'Histocompatibilit, , Paris, France
    Bone Marrow Transplant 30:497-502. 2002
    ..Our data indicate that the outcome of unrelated hematopoietic cell transplantation in terms of GVHD but also survival, could be improved through HLA-DPB1 matching or at least by avoiding two DPB1 mismatches...
  52. ncbi Human papillomavirus infection and anogenital condyloma in bone marrow transplant recipients
    M Daneshpouy
    Laboratoire de Recherche Universitaire de Pathologie, , H pital Saint-Louis, Paris, France
    Transplantation 71:167-9. 2001
    ..Because the oncoprotein of HPV is able to bind and to degrade p53, it may lead to genetic instability, and subsequently to malignant transformation...
  53. ncbi Hepatic veno-occlusive disease
    P Ribaud
    Federation d Hematologie, Service de Greffe de Moelle, Hopital St Louis, Paris, France
    Pediatr Transplant 3:41-4. 1999
    ..Its overall mortality rate is < 4% in adults as well as in children. Recent progress has been achieved in the diagnosis of this complication. However, better methods of both prophylaxis and treatment are needed...
  54. ncbi Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Ce
    P Guardiola
    Department of Hematology, Bone Marrow Transplant, Hopital Saint Louis, Paris, France
    Blood 93:2831-8. 1999
    ..A better characterization of the variables affecting the posttransplant outcome should lead to a decreased transplant-related mortality and an improvement in these results...
  55. ncbi Cord blood-circulating endothelial progenitors for treatment of vascular diseases
    M Lavergne
    ABCell Bio, Paris, France
    Cell Prolif 44:44-7. 2011
    ..This indicates that CB cryopreservation should be improved to preserve integrity of stem cells other than haematopoietic ones. Feasibility of using CB for clinical applications will be validated in porcine models of ischaemia...
  56. ncbi Cord blood transplant: strategy of alternative donor search
    Eliane Gluckman
    Hematology Bone Marrow Transplant Department and Eurocord office, Hospital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Springer Semin Immunopathol 26:143-54. 2004
    ..The option of performing cord blood transplants should be based on urgency of the transplant, cord blood cell dose and number of HLA disparities...
  57. ncbi Umbilical cord blood transplantation
    Vanderson Rocha
    Eurocord Office, Bone Marrow Transplant, Hematology Department, Hopital Saint Louis, Paris, France
    Curr Opin Hematol 11:375-85. 2004
    ..Cell dose and human leukocyte antigen are major factors influencing outcome after umbilical cord blood transplantation...
  58. ncbi Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies
    Vanderson Rocha
    Eurocord office and Acute Leukemia Working Party of the European Blood and Marrow Transplant Group, Hopital Saint Louis, Universite Paris 7, Paris, France
    Curr Opin Oncol 21:S31-4. 2009
    ..This paper will summarize some recent results of RIC UCBT for adults with haematological malignancies...
  59. ncbi Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors
    Vanderson Rocha
    Department of Haematology, Eurocord Netcord EBMT office, Institut universitaire, Hopital Saint Louis, Universite de Paris 7, 1 av Claude Vellefaux, 75010 Paris, France
    Br J Haematol 147:262-74. 2009
    ..This review will focus on the interactions between HLA, cell dose and other modifiable factors related to the UCB unit selection and transplantation that may improve outcomes after UCB transplantation...
  60. ncbi Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT
    Andree Laure Herr
    EUROCORD, Hopital Saint Louis, 1 Ave Claude Vellefaux, Quadrilatère porte 5, Paris Cedex 10, France
    Blood 116:1849-56. 2010
    ..Patients without advanced disease had improved DFS. These results support banking and use of CB units for RCBT. Cell dose, GVHD prophylaxis not including methotrexate, and disease status are important factors for outcomes after RCBT...
  61. ncbi Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation
    Juliana Fernandes
    Haematology Department and Bone Marrow Transplant Unit, Hopital Saint Louis, Paris, France
    Br J Haematol 137:248-51. 2007
    ..Acute GVHD grades II-IV was observed in three patients. Three are alive, between 12 and 25 months after dUCBT. In conclusion, dUCBT is a promising procedure to treat early GF...
  62. ncbi Human leukocyte antigen matching in cord blood transplantation
    Eliane Gluckman
    Department of Hematologie Bone Marrow Transplant, EUROCORD, Institute of Hematology, APHP Hospital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Semin Hematol 42:85-90. 2005
    ....
  63. ncbi Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey
    Vanderson Rocha
    Hematopoietic Stem Cell Transplant Unit, Hopital Saint Louis, and Service d Hématologie, CHU Saint Antoine and European Data Management Office, Institut des Cordeliers, Paris, France
    J Clin Oncol 20:4324-30. 2002
    ..Bone marrow cell dose has been reported to be an important factor in alloBMT; however, its true impact on relapse incidence (RI), leukemia-free survival (LFS), and nonrelapse mortality (NRM) in a large cohort of patients is unknown...
  64. ncbi Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplant
    Regis Peffault De Latour
    Bone Marrow Transplant Unit, Saint Louis Hospital, Paris, France
    Biol Blood Marrow Transplant 17:78-85. 2011
    ..9 10(7) TNCs/kg prefreezing (45%, compared with 18% for recipients of ≤ 3.9 10(7) TNC/kg; HR, 0.4; P = .007). These results highlight the fundamental role of cell dose for both engraftment and OS in patients with SAA undergoing UCBT...
  65. ncbi Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry
    D Farge
    St Louis Hospital, Paris, France
    Ann Rheum Dis 63:974-81. 2004
    ..This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases...
  66. ncbi Intermethod discordance for alpha-fetoprotein measurements in Fanconi anemia
    B Cassinat
    Nuclear Medicine Department, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, 75010 Paris, France
    Clin Chem 47:1405-9. 2001
    ..The aim of this study was to compare five AFP assays on FA and non-FA samples and to investigate possible explanations for FA-specific discrepancies...
  67. ncbi Effect of tresperimus on ex vivo expansion of CD34+CD38(-)-enriched cord blood cells
    S el Marsafy
    Laboratoire de Recherche sur la Biologie de la Moelle Osseuse, Institut Universitaire d Hematologie, EA 1814 Paris VII, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75475 Paris, France
    Haematologia (Budap) 32:327-36. 2002
    ....
  68. ncbi Accelerated telomere shortening and telomerase activation in Fanconi's anaemia
    F Leteurtre
    Service de Recherches en Hemato Immunologie, DSV DRM, CEA, Hopital Saint Louis, Paris, France
    Br J Haematol 105:883-93. 1999
    ..Telomerase, the enzyme that counteracts telomere shortening, was 4.8-fold more active in 25 FA patients than in 15 age-matched healthy controls. A model for the FA disease process is proposed...
  69. ncbi Imaging of diffuse metastatic and dystrophic pulmonary calcification in children after haematopoietic stem cell transplantation
    A Guermazi
    Department of Radiology, Saint-Louis University Hospital, AP-HP, 1 avenue Claude Vellefaux, 75010 Paris, France
    Br J Radiol 78:708-13. 2005
    ..Radiological characteristics, scintigraphic features, pathological mechanism and clinical outcome of such pulmonary calcification are discussed...
  70. ncbi [Use of hematopoietic stem cells from cord blood for allogenic transplantation in man]
    E Gluckman
    Service d hématologie greffe de moelle, Hopital Saint Louis, Paris
    Bull Acad Natl Med 182:337-48; discussion 349-50. 1998
    ..European results show that the number of hematopoietic stem cells present in one cord blood is sufficient to permanently engraft most of the patients. Graft versus host disease is decreased even in unrelated mismatched transplants...
  71. ncbi Clinical use of umbilical cord blood hematopoietic stem cells
    Vanderson Rocha
    Eurocord Office Bone Marrow Transplant Hematology Department, Hopital Saint Louis, Paris, France
    Biol Blood Marrow Transplant 12:34-41. 2006
    ..This review describes the recent clinical results and discusses developing research strategies aimed at optimizing the results of cord blood transplantation...
  72. ncbi Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease
    Marie Robin
    Bone Marrow Transplantation Unit, , Paris, France
    Transplantation 80:634-42. 2005
    ..0 x 10/L, and platelets >200 x 10/L had a better outcome. CONCLUSIONS: TAI is a safe and efficient option in patients with refractory chronic GvHD, leading to a significant tapering of systemic corticosteroid dose in most cases...
  73. ncbi Effective graft-versus-leukaemia effect after allogeneic stem cell transplantation using reduced-intensity preparative regimens in Fanconi anaemia patients with myelodysplastic syndrome or acute myeloid leukaemia
    Philippe Guardiola
    Bone Marrow Transplant Unit, , Paris, France
    Br J Haematol 122:806-9. 2003
    ..Even after transplantation, myeloid malignancies remain associated with a poor outcome in FA, and this argues in favour of early intervention when suitable donors are available...
  74. ncbi Little evidence of donor-derived epithelial cells in early digestive acute graft-versus-host disease
    Veronique Meignin
    Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris VII, Hopital Saint Louis, Paris, France
    Blood 103:360-2. 2004
    ..Donor-derived lymphoid cells were detected in the epithelium and the lamina propria, as expected. However, using our stringent criteria, no donor-derived cells could be proven to be epithelial...
  75. ncbi Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study
    Helene Esperou
    Hematology Department, St Louis Hospital, Assistance Publique Hopitaux de Paris AP HP, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Transplantation 77:1854-8. 2004
    ..Allogeneic hematopoietic stem-cell transplantation is a widely used, cost-intensive procedure. Our purpose was to estimate costs and determine cost predictors...
  76. ncbi Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow
    Norbert C Gorin
    Centre International Greffes de Moelle, Hopital Saint Antoine, AP HP, Paris, France
    Blood 102:3043-51. 2003
    ..64; 95% CI, 0.44-0.92; P =.016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich...
  77. ncbi Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants
    David Michonneau
    Service d Hématologie Greffe, Hopital Saint Louis, Paris, France
    Br J Haematol 145:107-14. 2009
    ..32, 95% confidence interval: 0.11-0.92, P = 0.035). In conclusion, a higher B lineage-specific hematopoietic progenitor cells (CD34(+) CD19(+)) cell dose is associated with a significant decrease incidence of acute GvHD...
  78. ncbi Chronic diarrhoea after allogenic bone marrow transplantation
    B Radu
    , , 1 avenue Claude Vellefaux, F75010, Paris, France
    Gut 54:161, 174. 2005
  79. ncbi Current status of umbilical cord blood hematopoietic stem cell transplantation
    E Gluckman
    Bone Marrow Transplant Hematology Department, Hospital Saint Louis, for the Eurocord Netcord Registry, Paris, France
    Exp Hematol 28:1197-205. 2000
    ..This large registry study confirms the potential benefit of using umbilical cord blood hematopoietic stem cells for allogeneic transplants...
  80. ncbi Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia
    Eliane Gluckman
    Hospital Saint Louis, Paris, France
    Br J Haematol 119:1075-82. 2002
    ..We conclude that lenograstim support of immunosuppressive therapy might be used for patients with severe aplastic anaemia as it significantly enhances neutrophil recovery but does not modify the overall response and survival...
  81. ncbi Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation
    Caroline Masserot
    Assistance Publique Hospitaux de Paris, Bone Marrow Transplant Unit, Saint Louis Hospital, Paris, France
    Cancer 113:3315-22. 2008
    ..Fanconi anemia (FA) is a chromosomal instability disorder with a very high risk of developing head and neck squamous cell carcinoma (HNSCC), most notably after hematopoietic stem cell transplantation (HSCT)...
  82. ncbi Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants
    Jerome Larghero
    Cell Therapy Unit, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, Paris, France
    Br J Haematol 138:101-9. 2007
    ..06 respectively). No specific cell subpopulation infused dose was associated with survival. In conclusion, a higher BM NK cell dose is associated with an increased speed of neutrophil recovery and a decreased incidence of cGvHD...
  83. ncbi Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation
    Ryad Tamouza
    Assistance publique Hôpitaux de Paris Groupement Hôspitalier et Universitaire Nord, Institut Universitaire d Hematologie, et Institut National de la Santé et de la Recherche Médicale U662, Hopital Saint Louis, Paris, France
    Transplantation 82:1436-40. 2006
    ..Given the dual role of human leukocyte antigen (HLA)-E molecules in innate and adaptive immune processes, we analyzed the impact of HLA-E polymorphism in genoidentical HSCT setting...
  84. ncbi Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation
    Veronique Meignin
    Unite INSERM U 728, Institut d Hematologie, Hopital Saint Louis, Paris, France
    Exp Hematol 33:894-900. 2005
    ..The long-term CD4+CD25high T-cell reconstitution after allogeneic stem cell transplantation is unknown. Here, we evaluated whether recovery of this T-cell subset might be linked to the establishment of full donor/recipient tolerance...
  85. ncbi Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders
    Felix Agbalika
    Department of Microbiology, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Br J Haematol 136:305-8. 2007
    ..High viral load was detected in peripheral blood mononuclear cells at PTLD diagnosis, independently of deleted LMP1. Detection of EA-IgG in allo-HSCT recipients pretransplantation might be considered as risk factor for PTLD development...
  86. ncbi Subtotal cystectomy with ileocystoplasty for severe hemorrhagic cystitis after bone marrow transplantation
    P Sebe
    Department of Urology, Hopital Tenon, Paris, France
    Urology 57:168. 2001
    ..Hematuria did not recur after surgery with a satisfactory functional result (follow-up 10 months to 17 years). Subtotal cystectomy with detubularized ileocystoplasty can be used to control life-threatening hemorrhagic cystitis...
  87. ncbi Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia
    S Dupuis-Girod
    Pediatric Endocrinology and Immuno-Hematology Departments, Physiology Laboratory, , Paris, France
    J Pediatr 138:129-33. 2001
    ..Growth hormone treatment produced catch-up growth in all cases. These findings suggest a common genetic origin...
  88. ncbi Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group
    Jean Donadieu
    Service d hémato oncologie pédiatrique, Hopital Trousseau, Paris, France
    Haematologica 90:45-53. 2005
    ..Granulocyte colony-stimulating factor (G-CSF) therapy has significantly reduced the frequency and severity of infections, but its possible influence on the risk of malignancy is not known...
  89. ncbi Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation
    Anne Janin
    INSERM, U728, Paris, France
    Blood 113:1834-40. 2009
    ..Our observations therefore show that marrow cells in humans have a major role in epithelial cancer formation after allogeneic transplantation...
  90. ncbi Abnormal telomere metabolism in Fanconi's anaemia correlates with genomic instability and the probability of developing severe aplastic anaemia
    Xiaxin Li
    Bone Marrow Biology Laboratory, DRED University, Paris, France
    Br J Haematol 120:836-45. 2003
    ..These data indicated that telomeres might play a role in the evolution of bone marrow failure and malignant transformation in FA...
  91. ncbi A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation
    Kimmo Talvensaari
    Laboratoire d'Immunologie et d'Histocompatibilit, INSERM U.396, , , AP-HP, Paris, France
    Blood 99:1458-64. 2002
    ..These data indicate an efficient thymic regeneration pathway from CB lymphoid progenitors despite the low number of cells infused compared to bone marrow, arguing for a complete clinical immune recovery after CB transplantation...
  92. ncbi Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation
    Flore Sicre de Fontbrune
    Hematologie Greffe, Universite Paris 7, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris, France
    Clin Infect Dis 45:1019-24. 2007
    ..Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate...
  93. ncbi Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation
    Henrique Bittencourt
    Bone Marrow Transplant Unit, Cell Therapy Laboratory and Biostatistics Unit, Hospital Saint-Louis, Paris, France
    Blood 99:2726-33. 2002
    ..In conclusion a CD34(+) cell dose of 3 x 10(6)/kg or more improved all hematopoietic recoveries, decreased the incidence of fungal infections and TRM, and improved overall survival...
  94. ncbi Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation
    Hélène Moins-Teisserenc
    Laboratoire d Immunologie et d Histocompatibilité, Centre d Investigations Biomédicales Hématologie Oncologie Greffes, Paris, France
    J Infect Dis 198:818-26. 2008
    ..Evaluation of CMV-specific immune responses during the first episode of reactivation, together with extended phenotypes, could thus improve immune monitoring, especially in recipients at risk of uncontrolled viral reactivation...
  95. ncbi Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease
    Marjan Daneshpouy
    Laboratoire de Recherche Universitaire de Pathologie UPRES EA 2378, , , Greffes de Moelle Osseuse, , Paris, France
    Blood 99:3033-40. 2002
    ..Systematic duodenal biopsy performed at the onset of digestive symptoms should allow early GVHR detection, and pathologic signs of GVHR, together with eosinophil density, might help modulate immunosuppressive therapy...
  96. ncbi Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation
    Vanderson Rocha
    Hematology Department and Bone Marrow Transplant Unit, Hopital Saint Louis, Paris, France
    Blood 100:3908-18. 2002
    ..004). In conclusion, donor and recipient gene polymorphisms are informative genetic risk factors for selecting donor/recipient pairs and could help in the understanding of mechanisms involved in host defenses of BM transplant recipients...
  97. ncbi Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
    Philippe Guardiola
    Service de Greffe de Moelle, Hopital Saint Louis, Paris, France
    Blood 99:4370-8. 2002
    ....
  98. ncbi MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease
    Wahid Boukouaci
    Laboratoire d Immunologie et d Histocompatibilité, Centre d Innovations Biomédicales Hématologie Oncologie Greffe CIB HOG, Institut Universitaire d Hématologie IUH, and INSERM, UMRS, 940, Hopital Saint Louis, Paris, France
    Blood 114:5216-24. 2009
    ..Altogether, these data suggest that the studied MICA genotype and phenotype specificities could be used as relevant biomarkers for cGVHD monitoring...
  99. ncbi CT and MR imaging of central nervous system effects of therapy in patients treated for hematological malignancies
    Ali Guermazi
    Department of Radiology, Saint Louis Hospital AP HP, Paris, France
    Eur Radiol 13:L202-14. 2003
    ....
  100. ncbi Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy
    Emmanuel Clave
    Laboratoire d'Immunologie et d'Histocompatibilit, , , AP/HP, , Paris, France
    Transplantation 77:76-84. 2004
    ....
  101. ncbi Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression
    Gerard Socie
    Service d hématologie greffe de moelle, INSERM ERM 0220, Université Paris VII and Hôpital Saint Louis, Paris, France
    Blood 103:50-7. 2004
    ..One-year TRM associated with the same 2 factors and with chronic GvHD...